- Region
- Águilas
- Alhama de Murcia
- Jumilla
- Lorca
- Los Alcázares
- Mazarrón
- San Javier
-
ALL AREAS & TOWNS
- AREAS
- SOUTH WEST
- MAR MENOR
- MURCIA CITY & CENTRAL
- NORTH & NORTH WEST
- TOWNS
- Abanilla
- Abarán
- Aguilas
- Alamillo
- Alcantarilla
- Aledo
- Alhama de Murcia
- Archena
- Balsicas
- Blanca
- Bolnuevo
- Bullas
- Cañadas del Romero
- Cabo de Palos
- Calasparra
- Camping Bolnuevo
- Campo De Ricote
- Camposol
- Canada De La Lena
- Caravaca de la Cruz
- Cartagena
- Cehegin
- Ceuti
- Cieza
- Condado de Alhama
- Corvera
- Costa Cálida
- Cuevas De Almanzora
- Cuevas de Reyllo
- El Carmoli
- El Mojon
- El Molino (Puerto Lumbreras)
- El Pareton / Cantareros
- El Raso
- El Valle Golf Resort
- Fortuna
- Fuente Alamo
- Hacienda del Alamo Golf Resort
- Hacienda Riquelme Golf Resort
- Isla Plana
- Islas Menores & Mar de Cristal
- Jumilla
- La Azohia
- La Charca
- La Manga Club
- La Manga del Mar Menor
- La Pinilla
- La Puebla
- La Torre
- La Torre Golf Resort
- La Unión
- Las Palas
- Las Ramblas
- Las Ramblas Golf
- Las Torres de Cotillas
- Leiva
- Librilla
- Lo Pagan
- Lo Santiago
- Lorca
- Lorquí
- Los Alcázares
- Los Balcones
- Los Belones
- Los Canovas
- Los Nietos
- Los Perez (Tallante)
- Los Urrutias
- Los Ventorrillos
- Mar De Cristal
- Mar Menor
- Mar Menor Golf Resort
- Mazarrón
- Mazarrón Country Club
- Molina de Segura
- Moratalla
- Mula
- Murcia City
- Murcia Property
- Pareton
- Peraleja Golf Resort
- Perin
- Pilar de la Horadada
- Pinar de Campoverde
- Pinoso
- Playa Honda
- Playa Honda / Playa Paraíso
- Pliego
- Portmán
- Pozo Estrecho
- Puerto de Mazarrón
- Puerto Lumbreras
- Puntas De Calnegre
- Region of Murcia
- Ricote
- Roda Golf Resort
- Roldan
- Roldan and Lo Ferro
- San Javier
- San Pedro del Pinatar
- Santiago de la Ribera
- Sierra Espuña
- Sucina
- Tallante
- Terrazas de la Torre Golf Resort
- Torre Pacheco
- Totana
- What's On Weekly Bulletin
- Yecla
- EDITIONS: Spanish News Today Alicante Today Andalucia Today
ARCHIVED - Pfizer coronavirus vaccine has 90 per cent effectivity says pharmaceutical giant
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.
After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”
“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”
“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.
Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.
Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.
Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Cartagena
El Carmoli
Islas Menores and Mar de Cristal
La Manga Club
La Manga del Mar Menor
La Puebla
La Torre Golf Resort
La Union
Los Alcazares
Los Belones
Los Nietos
Los Urrutias
Mar Menor Golf Resort
Pilar de la Horadada
Playa Honda / Playa Paraiso
Portman
Roldan and Lo Ferro
San Javier
San Pedro del Pinatar
Santa Rosalia Lake and Life resort
Terrazas de la Torre Golf Resort
Torre Pacheco
Aledo
Alhama de Murcia
Bolnuevo
Camposol
Condado de Alhama
Fuente Alamo
Hacienda del Alamo Golf Resort
Lorca
Mazarron
Puerto de Mazarron
Puerto Lumbreras
Sierra Espuna
Totana
Abaran
Alcantarilla
Archena
Blanca
Corvera
El Valle Golf Resort
Hacienda Riquelme Golf Resort
Lorqui
Molina de Segura
Mosa Trajectum
Murcia City
Peraleja Golf Resort
Ricote
Sucina
Condado de Alhama
El Valle Golf Resort
Hacienda del Alamo Golf Resort
Hacienda Riquelme Golf Resort
Islas Menores and Mar de Cristal
La Manga Club
La Torre Golf Resort
Mar Menor Golf Resort
Mazarron Country Club
Mosa Trajectum
Peraleja Golf Resort
Santa Rosalia Lake and Life resort
Terrazas de la Torre Golf Resort
La Zenia
Lomas de Cabo Roig
CAMPOSOL TODAY Whats OnCartagena SpainCoronavirusCorvera Airport MurciaMurcia Gota Fria 2019Murcia property news generic threadWeekly Bulletin